Medically reviewed by Nachiket J. Patel, MD, FACC, FSCAI. Last medically reviewed: August 2026.
A cholesterol report can look like a contest between one “good” number and one “bad” number. That is too simple.
LDL cholesterol, non-HDL cholesterol, triglycerides, HDL cholesterol, and lipoprotein(a) describe different parts of cardiovascular risk. None should be read without the patient’s blood pressure, diabetes status, kidney function, tobacco exposure, family history, and any evidence of plaque.
The useful question is not merely, “Is this result inside the laboratory range?” It is, “What does this result mean for this person, and would acting on it reduce the chance of heart attack, stroke, or vascular disease?”
LDL cholesterol: the main treatment target
LDL cholesterol, or LDL-C, estimates the cholesterol carried in low-density lipoprotein particles. These particles can enter artery walls and contribute to atherosclerotic plaque.
For that reason, LDL remains a principal treatment target. But the same LDL value does not carry the same meaning for everyone. A person with a previous heart attack, coronary stent, stroke, or peripheral artery disease generally needs more intensive LDL lowering than someone with no known plaque and otherwise low risk.
Duration matters as well. Years of exposure to elevated LDL can influence lifetime risk even when a younger adult’s short-term risk estimate appears modest.
Non-HDL cholesterol: a broader view of plaque-forming particles
Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It includes LDL plus cholesterol carried by several other particles that may contribute to atherosclerosis.
This number can be particularly informative when triglycerides are elevated, diabetes or metabolic disease is present, or LDL does not seem to tell the whole story. It does not require a separate blood test; it is calculated from the standard lipid panel.
In selected patients, apolipoprotein B, or apoB, can provide another estimate of the number of potentially atherogenic particles. ApoB is not necessary for every patient, but it may clarify residual risk when triglycerides are high or metabolic disease and established cardiovascular disease are present.
Triglycerides: related, but not interchangeable with LDL
Triglycerides are a form of fat used for energy storage. They may rise with excess alcohol, poorly controlled diabetes, weight gain, certain medications, genetic conditions, and diets high in refined carbohydrates or added sugars.
Moderately elevated triglycerides often travel with insulin resistance and other cardiovascular risk factors. Very high levels raise a separate concern: pancreatitis. The response therefore depends on both the triglyceride level and its likely cause.
Physical activity, weight change when appropriate, improved diabetes control, and reducing excess alcohol or refined carbohydrates may produce meaningful improvement. Medication decisions depend on the degree of elevation and the patient’s cardiovascular and pancreatitis risk.
A routine lipid profile can often be obtained without fasting. A fasting sample may be more useful when triglycerides are markedly elevated, when a previous result is difficult to interpret, or when an inherited lipid disorder is suspected.
HDL cholesterol: useful context, not a shield
HDL cholesterol is included in cardiovascular risk assessment, but a high HDL value does not erase elevated LDL, tobacco exposure, diabetes, or known plaque. Medicines intended only to raise HDL have not established that a higher laboratory number by itself produces the expected cardiovascular protection.
It is better to treat HDL as one part of the risk picture than as permission to ignore the other findings.
Lipoprotein(a): an inherited risk marker worth checking once
Lipoprotein(a), usually abbreviated Lp(a), is an LDL-like particle whose level is largely inherited. It is not included in a standard lipid panel.
The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood. A high result can help explain cardiovascular disease that seems earlier or more extensive than expected, particularly in a family with premature heart attack or stroke.
Lifestyle changes have little effect on the Lp(a) concentration itself. That does not make lifestyle irrelevant. A high Lp(a) result can make careful control of modifiable risks—LDL, blood pressure, diabetes, and tobacco exposure—even more important.
Because Lp(a) is usually stable and genetically determined, repeated testing is generally unnecessary unless a clinician identifies a specific reason.
Why the target is different for different people
Current prevention decisions increasingly combine laboratory results with a person’s overall and long-term risk. Relevant information includes:
- Known coronary, carotid, or peripheral arterial plaque
- Previous heart attack, stroke, or arterial procedure
- High blood pressure
- Diabetes or chronic kidney disease
- Current tobacco use
- An untreated LDL of 190 mg/dL or higher
- A strong family history of premature cardiovascular disease
- Elevated Lp(a)
- Evidence of coronary plaque on imaging
When the decision about cholesterol medication remains uncertain, a carefully selected coronary calcium score may help. The scan should be ordered because its result could change the plan—not simply to collect another number.
What to ask at your next visit
Bring prior lipid results if possible. A trend may be more informative than one isolated panel. Useful questions include:
- What is my estimated cardiovascular risk over both the next decade and the longer term?
- Is LDL sufficient for my situation, or would non-HDL cholesterol, apoB, or Lp(a) add useful information?
- Could a medication, medical condition, or family disorder be affecting these results?
- What degree of LDL reduction would meaningfully change my risk?
- When should the panel be repeated after a treatment change?
For people taking lipid-lowering treatment, current guidance recommends checking a lipid profile 4 to 12 weeks after starting or adjusting therapy and then every 6 to 12 months once the response is stable. The schedule should still be individualized.
A strong prevention plan does not chase every laboratory value. It identifies the measurements that matter, explains the uncertainty honestly, and connects treatment to an outcome the patient cares about.
Sources and Further Reading
- 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia — JACC
- 2026 Dyslipidemia Guideline Hub — JACC
- Top 10 Things to Know About the 2026 Cholesterol Guideline — American Heart Association
Related heart and vascular information
- Hyperlipidemia (High Cholesterol)
- Coronary Artery Disease
- Peripheral Artery Disease
- Cardiac CT and Coronary Calcium Scoring
Schedule an appointment
If you would like a focused review of your symptoms, risk, testing, or treatment options, request an appointment with Flow Heart & Vascular in Mesa, Arizona.
This article provides general education and does not replace individualized medical advice, diagnosis, or emergency care. Do not start, stop, or change medication or delay emergency care based only on information on this website.
